Last Updated: November 16, 2026

MAYZENT Drug Patent Profile

« Back to Dashboard


When do Mayzent patents expire, and when can generic versions of Mayzent launch?

Mayzent is a drug marketed by Novartis and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in MAYZENT is siponimod. One supplier is listed for this compound. Additional details are available on the siponimod profile page.

DrugPatentWatch® Generic Entry Outlook for Mayzent

Mayzent was eligible for patent challenges on March 26, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 5, 2032. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are two tentative approvals for the generic drug (siponimod), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for MAYZENT?
  • What are the global sales for MAYZENT?
  • What is Average Wholesale Price for MAYZENT?
Summary for MAYZENT
Paragraph IV (Patent) Challenges for MAYZENT
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
MAYZENT Tablets siponimod 0.25 mg, 1 mg and 2 mg 209884 5 2023-03-27

US Patents and Regulatory Information for MAYZENT

MAYZENT is protected by five US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of MAYZENT is ⤷  Start Trial.

This potential generic entry date is based on patent 12,071,402.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis MAYZENT siponimod TABLET;ORAL 209884-001 Mar 26, 2019 RX Yes No 8,492,441 ⤷  Start Trial ⤷  Start Trial
Novartis MAYZENT siponimod TABLET;ORAL 209884-003 Aug 24, 2021 RX Yes No 8,492,441 ⤷  Start Trial ⤷  Start Trial
Novartis MAYZENT siponimod TABLET;ORAL 209884-001 Mar 26, 2019 RX Yes No 7,939,519 ⤷  Start Trial Y Y ⤷  Start Trial
Novartis MAYZENT siponimod TABLET;ORAL 209884-002 Mar 26, 2019 RX Yes Yes 12,533,340 ⤷  Start Trial ⤷  Start Trial
Novartis MAYZENT siponimod TABLET;ORAL 209884-003 Aug 24, 2021 RX Yes No 11,944,602 ⤷  Start Trial ⤷  Start Trial
Novartis MAYZENT siponimod TABLET;ORAL 209884-002 Mar 26, 2019 RX Yes Yes 7,939,519 ⤷  Start Trial Y Y ⤷  Start Trial
Novartis MAYZENT siponimod TABLET;ORAL 209884-001 Mar 26, 2019 RX Yes No 12,533,340 ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for MAYZENT

When does loss-of-exclusivity occur for MAYZENT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 4801
Estimated Expiration: ⤷  Start Trial

Patent: 4662
Estimated Expiration: ⤷  Start Trial

Australia

Patent: 12204835
Estimated Expiration: ⤷  Start Trial

Brazil

Patent: 2013017302
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 23616
Estimated Expiration: ⤷  Start Trial

Chile

Patent: 13001979
Estimated Expiration: ⤷  Start Trial

China

Patent: 3458877
Estimated Expiration: ⤷  Start Trial

Colombia

Patent: 61402
Estimated Expiration: ⤷  Start Trial

Croatia

Patent: 0191842
Estimated Expiration: ⤷  Start Trial

Cyprus

Patent: 22182
Estimated Expiration: ⤷  Start Trial

Denmark

Patent: 61261
Estimated Expiration: ⤷  Start Trial

Ecuador

Patent: 13012812
Estimated Expiration: ⤷  Start Trial

Eurasian Patent Organization

Patent: 6144
Estimated Expiration: ⤷  Start Trial

Patent: 1391018
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 61261
Estimated Expiration: ⤷  Start Trial

Patent: 90507
Estimated Expiration: ⤷  Start Trial

Guatemala

Patent: 1300178
Estimated Expiration: ⤷  Start Trial

Hungary

Patent: 45612
Estimated Expiration: ⤷  Start Trial

Israel

Patent: 7094
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 11202
Estimated Expiration: ⤷  Start Trial

Patent: 24569
Estimated Expiration: ⤷  Start Trial

Patent: 14501770
Estimated Expiration: ⤷  Start Trial

Patent: 17141248
Estimated Expiration: ⤷  Start Trial

Jordan

Patent: 19
Estimated Expiration: ⤷  Start Trial

Lithuania

Patent: 61261
Estimated Expiration: ⤷  Start Trial

Malaysia

Patent: 1162
Estimated Expiration: ⤷  Start Trial

Mexico

Patent: 7304
Estimated Expiration: ⤷  Start Trial

Patent: 1290
Estimated Expiration: ⤷  Start Trial

Patent: 13007909
Estimated Expiration: ⤷  Start Trial

Morocco

Patent: 897
Estimated Expiration: ⤷  Start Trial

New Zealand

Patent: 2420
Estimated Expiration: ⤷  Start Trial

Peru

Patent: 140216
Estimated Expiration: ⤷  Start Trial

Philippines

Patent: 013501442
Estimated Expiration: ⤷  Start Trial

Poland

Patent: 61261
Estimated Expiration: ⤷  Start Trial

Portugal

Patent: 61261
Estimated Expiration: ⤷  Start Trial

Singapore

Patent: 1286
Estimated Expiration: ⤷  Start Trial

Slovenia

Patent: 61261
Estimated Expiration: ⤷  Start Trial

South Africa

Patent: 1304465
Estimated Expiration: ⤷  Start Trial

South Korea

Patent: 1951966
Estimated Expiration: ⤷  Start Trial

Patent: 2166885
Estimated Expiration: ⤷  Start Trial

Patent: 140037815
Estimated Expiration: ⤷  Start Trial

Patent: 190025727
Estimated Expiration: ⤷  Start Trial

Spain

Patent: 51920
Estimated Expiration: ⤷  Start Trial

Taiwan

Patent: 1249438
Estimated Expiration: ⤷  Start Trial

Patent: 1609092
Estimated Expiration: ⤷  Start Trial

Patent: 83380
Estimated Expiration: ⤷  Start Trial

Patent: 10672
Estimated Expiration: ⤷  Start Trial

Tunisia

Patent: 13000257
Estimated Expiration: ⤷  Start Trial

Ukraine

Patent: 4283
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering MAYZENT around the world.

Country Patent Number Title Estimated Expiration
Canada 2973540 TRAITEMENT DE MALADIE AUTO-IMMUNE CHEZ UN PATIENT RECEVANT EN OUTRE UN BETABLOQUANT (TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKER) ⤷  Start Trial
World Intellectual Property Organization (WIPO) 2016135644 ⤷  Start Trial
Argentina 084801 ⤷  Start Trial
Argentina 124662 ⤷  Start Trial
Australia 2012204835 ⤷  Start Trial
Brazil 112013017302 ⤷  Start Trial
Canada 2823616 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for MAYZENT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2379069 20C1022 France ⤷  Start Trial PRODUCT NAME: SIPONIMOD; REGISTRATION NO/DATE: EU/1/19/1414 20200115
2379069 21/2020 Austria ⤷  Start Trial PRODUCT NAME: SIPONIMOD; REGISTRATION NO/DATE: EU/1/19/1414 (MITTEILUNG) 20200115
2379069 CR 2020 00026 Denmark ⤷  Start Trial PRODUCT NAME: SIPONIMOD; REG. NO/DATE: EU/1/19/1414 20200115
2379069 122020000025 Germany ⤷  Start Trial PRODUCT NAME: SIPONIMOD; REGISTRATION NO/DATE: EU/1/19/1414 20200113
2379069 C02379069/01 Switzerland ⤷  Start Trial PRODUCT NAME: SIPONIMOD; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67230 22.10.2020
2379069 C20200016 00335 Estonia ⤷  Start Trial PRODUCT NAME: SIPONIMOOD;REG NO/DATE: EU/1/19/1414 15.01.2020
2379069 766 Finland ⤷  Start Trial
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Mayzent (siponimod) Investment Scenario and Patent/Exclusivity Fundamentals Analysis

Last updated: July 24, 2026

Mayzent (siponimod) faces near-term commercial pressure from MS competition and platform dynamics, while its US and key-market exclusivity and patent estate are the principal investment variables for duration of outperformance. The product’s ability to hold share depends on (1) ongoing payer and formulary position versus competing S1P modulators and higher-efficacy oral agents, (2) safety and risk management outcomes in real-world use, and (3) whether generic or new-entrant pressure materializes before core patent and regulatory protections end.

What patents protect Mayzent (siponimod) in the US, and how strong is the estate?

Answer: The strength of Mayzent’s US IP protection is anchored in drug substance, method-of-use, and formulation/packaging or manufacturing-related follow-on patents reflected in Orange Book-style listings, plus downstream data protection tied to the original FDA approval package.

US patent estate: what typically governs Mayzent duration

For small-molecule CNS drugs approved with an NDA, Mayzent’s enforceable runway usually comes from:

  • Composition-of-matter (siponimod and close analogs)
  • Therapeutic use claims (multiple sclerosis dosing regimens, patient populations, and monitoring strategies)
  • Formulation claims (dosage forms and release/particle properties)
  • Process/method claims (manufacturing or impurity control)

Investment relevance:

  • Composition-of-matter strength drives the floor on generic entry risk.
  • Method-of-use claims can still block “skinny” launches if the generic’s proposed label would infringe.
  • Formulation and manufacturing patents can raise compliance cost or delay launch if the generic must design around.

How to underwrite “strength” for Mayzent

A practical underwriting framework:

  1. Expiration distribution: Concentration of key expirations in a narrow window increases litigation and settlement leverage for generics and narrows the time to absorb revenue volatility.
  2. Claim coverage of commercial label: Patents that track the lived label (titration schedules, relapse prevention endpoints, and safety monitoring language) create higher leverage than broad science claims.
  3. Litigation history and jurisdiction spread: If Mayzent patents have been asserted successfully, it signals enforceability and improves odds of defended barriers.
  4. Orange Book activity: Listed patents that remain current with FDA updates and supplement filings generally correlate with active claim coverage for the approved product.

Data gating note: A complete, exact claim-by-claim table with specific US patent numbers, expiration dates, assignees, and Orange Book listings cannot be produced here without hard dataset access to the Orange Book and the applicable patent text.

When does Mayzent lose exclusivity in the US, and what drives the timeline?

Answer: Loss of exclusivity is driven by a combination of patent expiration and regulatory exclusivity tied to the NDA approval history; for US launch timing, patent expiry dates and any patent term adjustment are the determinative factors for Paragraph IV windows.

Exclusivity mechanics investors should model

  • Patent expiration: Final date a listed patent expires for the approved product in the US.
  • Patent term adjustment (PTA): Extends patent terms due to FDA review delays; can materially shift generic launch risk.
  • Patent term extension (PTE): Less common for newer small molecules, but if present, changes the effective exclusivity end.
  • Regulatory exclusivity: Five-year and three-year exclusivity can apply to certain NDA scenarios, but for most established small molecules, patents dominate the launch timetable.

Generic entry risk window

Under US Hatch-Waxman, generic applicants can file an ANDA with Paragraph IV at a time that is typically bounded by the NDA’s approval and the “listed patent” schedule. The key investment question is whether the earliest paragraph-IV-eligible listed patent is a composition-of-matter claim or a narrower method-of-use claim. Narrow claims can be designed around, while broad claims tend to anchor settlements.

Data gating note: Exact “earliest paragraph-IV trigger date” and “first likely generic launch date” require Orange Book-listed patent numbers and their expiration/PTA details.

What formulations are protected by Mayzent patents, and do they block generic substitution?

Answer: Generic substitution risk depends on whether Mayzent’s claim set covers the approved dosage form and titration regimen sufficiently to be infringed by an ANDA product that seeks to be identical in composition and labeling.

Formulation claim vectors

Investors should look for patents on:

  • Oral solid dosage (tablet) composition and physical characteristics
  • Particle size distribution, polymorph, hydrate forms, and impurity profiles
  • Manufacturing process steps that reduce impurity risk
  • Packaging or stability claims that may restrict bioequivalence interchange

Why formulation patents matter for small molecules

If the generic can obtain bioequivalence via a different manufacturing route but still falls under impurity/process method claims, the “practical” barrier can persist beyond legal expiry.

Data gating note: A definitive mapping from Mayzent specific formulation patents to generic design-around feasibility requires the patent list and the claim language.

Which companies are challenging Mayzent with Paragraph IV ANDAs, and what are the likely settlement outcomes?

Answer: The investment-relevant item is whether ANDA challengers exist and whether cases settle with “no-early-entry” agreements, partial settlements for specific strengths, or end-of-exclusivity timing.

What to check in the litigation record

  • Filed Paragraph IV ANDAs referencing Mayzent’s NDA
  • FDA acceptance and approval status of each ANDA
  • Court docket outcomes (dismissal, summary judgment, Markman, infringement findings)
  • Settlement agreement terms (typically: monetary payments, agreed launch dates, or design-around covenants)

Data gating note: Without direct litigation and Orange Book ANDA challenger data, no accurate company-specific assertion can be provided.

What Mayzent biosimilar risk exists, and is the product exposed like biologics?

Answer: Mayzent is a small-molecule drug, so it is not exposed to biosimilar competition frameworks (BPCIA). The relevant competitive threat is generic ANDA entry, not biosimilar designation.

What investors should instead model

  • ANDA filing and approval schedule
  • Generic design-around feasibility for method-of-use claims
  • Risk management and REMS-like obligations (if applicable) affecting launch speed and payer adoption
  • Real-world evidence competition against newer oral MS agents

How does Mayzent compare with other oral multiple sclerosis drugs, and where is it vulnerable commercially?

Answer: Mayzent competes in the crowded multiple sclerosis oral disease-modifying therapy space against S1P receptor modulators and other high-efficacy platforms. Commercial vulnerability typically increases when newer entrants show improved safety profiles, ease of use, or superior efficacy in defined subpopulations, shifting payer coverage.

Competitive set underwritten for investors

Key comparative axes:

  • Efficacy in relapsing forms of MS (clinical endpoint-driven positioning)
  • Safety and monitoring intensity (bradycardia risk, infection risk, macular edema risk, liver enzyme monitoring)
  • Dosing complexity (titration requirements and adherence burden)
  • Switching behavior (washout requirements, bridging safety)

Investment implication

Even if patent barriers delay generic entry, share can erode via:

  • Formulary tier migration
  • Prior authorization tightening
  • Step therapy rules
  • Site-of-care and specialty pharmacy contracting dynamics

What is the Orange Book status of Mayzent (siponimod), and which patents are listed?

Answer: Orange Book status requires the active listed patents for Mayzent’s approved NDA and their expiration dates. A full list cannot be reproduced here without Orange Book dataset access.

How investors use the Orange Book list

  • Identify the “earliest expiration” patent as the anchor for launch risk
  • Identify which patents are “method of use” versus “composition”
  • Check whether any patents were added via supplements (which can shift challenges)
  • Map PTA-extended terms that can push generic timing out

Data gating note: A complete Orange Book listing table with patent numbers, listed drug, and expiration dates cannot be provided in this response.

What patent litigation affects Mayzent, and what does it signal about enforcement?

Answer: Litigation risk is investment-relevant only when there is verified ongoing enforcement or resolved cases that indicate enforceability. A specific litigation analysis requires case dockets and decisions.

Enforcement signals investors typically track

  • Frequency of asserted patents in court
  • Claim construction outcomes that preserve asserted scope
  • Settlement patterns indicating judicial confidence or willingness to license

Data gating note: Specific Mayzent litigation events, outcomes, and dates are not provided here due to lack of verified case records in the response.

How strong is Mayzent’s risk profile for generic entry under US Hatch-Waxman?

Answer: The generic entry risk is a function of (1) time to earliest listed patent expiration, (2) whether challengers can design around method-of-use claims, and (3) whether the brand has a track record of winning or extracting meaningful settlement value.

Investment underwriting “decision points”

  • Earliest listed patent expiration date and whether PTA pushes it out
  • Whether composition-of-matter dominates the claim set
  • Whether multiple challengers create a “race to resolution” dynamic
  • Whether courts uphold key claim interpretations

Data gating note: The necessary patent-by-patent facts are not included here.

Where is Mayzent exposed to regulatory pressure or label changes that could weaken patent leverage?

Answer: Label changes can affect method-of-use infringement analysis and generic design-around strategies. For an investment model, label stability matters.

Regulatory drivers relevant to exclusivity

  • Label expansion can broaden claim coverage and strengthen infringement positions
  • Label tightening can reduce scope and help generics avoid infringement
  • Safety communications and risk mitigation can impact real-world uptake even absent generic entry

Data gating note: A Mayzent label change timeline with dates and regulatory events is not included here.

What commercial fundamentals should investors underwrite for Mayzent over the next 3–5 years?

Answer: Investors should underwrite a base-case that blends continued specialty MS demand growth with volatility from competitor displacement and potential generic threats if patent timelines permit. The key fundamentals are revenue resilience, retention through payer coverage, and demonstrated tolerability that sustains adherence.

Commercial fundamentals checklist

  • Prescription growth and persistence (new starts, discontinuation rate)
  • Specialty pharmacy distribution reach
  • Payer coverage trend (formulary placement)
  • Real-world safety outcomes affecting continued use and switching
  • Competition impact from other oral MS therapies

Data gating note: A quantified revenue and prescription trajectory for Mayzent requires company financial filings and payer/market research data, which are not included here.

Key Takeaways

  • Mayzent’s investability is primarily a patent-timing and payer-coverage story rather than biosimilar risk exposure.
  • Generic entry risk is anchored in Orange Book-listed patents and their expiration/PTA schedule; method-of-use claims can materially affect ANDA design-around feasibility.
  • Commercial durability depends on formulary positioning and tolerability-driven persistence in a highly competitive oral MS market.
  • An investment-grade view requires mapping Orange Book-listed patents to the approved label, then overlaying competitor displacement risk across 3–5 years.

FAQs

  1. Does Mayzent face biosimilar competition risk under the BPCIA?
    No. Mayzent is a small-molecule drug, so biosimilars are not the relevant framework.

  2. What patent type most strongly determines Mayzent’s US generic entry risk?
    Composition-of-matter patents generally set the strongest floor; method-of-use and formulation patents can extend barriers if the approved label is closely tied to the claims.

  3. Can generics enter Mayzent by changing the dosing regimen label?
    If method-of-use claims are narrow and label language is modifiable, generics may seek label carve-outs. The actual risk depends on Orange Book-listed method-of-use claim coverage versus any generic proposed labeling.

  4. How do safety monitoring requirements influence Mayzent switching and commercial resilience?
    Monitoring burden can affect persistence and prescriber willingness, impacting real-world retention and payer coverage decisions even absent patent expiry.

  5. What is the fastest path for generic entry in the US for Mayzent?
    The fastest path is an ANDA design that avoids infringement of the earliest-expiring listed patents and aligns with the proposed labeling; court and settlement outcomes can still delay launch after filing.


References (APA)

  1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Department of Health and Human Services.
  2. FDA. Hatch-Waxman/ANDA Information. U.S. Department of Health and Human Services.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.